Modelling the evolution of drug resistance in the presence of antiviral drugs

BMC Public Health

Volumn 7, Issue , 2007, Pages

  Wu, Jianhong ^a   Yan, Ping ^b   Archibald, Chris ^b  

^a YORK UNIVERSITY   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ARTICLE; CANADA; CLINICAL RESEARCH; COMPARTMENT MODEL; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLUENZA; MATHEMATICAL MODEL; PANDEMIC; PREDICTION; PUBLIC HEALTH SERVICE; SCIENTIST; STATISTICAL ANALYSIS; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG EFFECT; EPIDEMIC; HEALTH CARE PLANNING; THEORETICAL MODEL; VIROLOGY;

ANTIVIRAL AGENTS; CANADA; DISEASE OUTBREAKS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEALTH PRIORITIES; HUMANS; INFLUENZA, HUMAN; MODELS, THEORETICAL; POPULATION SURVEILLANCE;

EID: 37349105333     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-7-300     Document Type: Article

References (30)

1. Paediatric HIV and treatment of children living with HIV. http://www.who.int/hiv/paediatric/en/index.html
2. HIV Drug Resistance. http://www.who.int/hiv/drugresistance/en/
3. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. http://www.who.int/3by5/publications/ documents/arv_guidelines/en/
4. HIV/AIDS Publications, Guidelines. http://www.who.int/hiv/pub/guidelines/ en/index.html
5. Early detection of HIV infection in infants andchildren. http://www.who.int/hiv/paediatric/EarlydiagnostictestingforHIVVer_Final_May07. pdf
6. Scaling-up HIV testing and counselling (TC) services. http://www.who.int/hiv/topics/vct/toolkit/en/index.html
7. A tale of two futures: HIV and antiretroviral therapy in San Francisco. S Blower H Gershengorn R Grant, Science 2000 287 650 654 10.1126/science.287. 5453.650 10649998
8. Predicting the unpredictable: transmission of drug resistant HIV. S Blower A Aschenbach H Gershengorn J Kahn, Nature Medicine 2001 7 1016 1020 10.1038/nm0901-1016 11533704
9. Uncertainty and Sensitity Analysis. http://www.semel.ucla.edu/ biomedicalmodeling/usa.asp
10. Could widespread usage of combination antiretroviral therapy eradicate HIV epidemics? J Velasco-Hernandez H Gershengorn S Blower, The Lancet Infectious Diseases 2002 2 487 493 10.1016/S1473-3099(02)00346-8 12150848
11. Predicting the transmission of drug-resistant HIV: comparing theory with data. S Blower A Aschenbach J Kahn, The Lancet Infectious Diseases 2003 3 10 12 10.1016/S1473-3099(03)00479-1 12505024
12. Predicting the public health impact of antiretrovirals: preventing HIV in developing countries. S Blower P Farmer, AIDScience 2003 3 11
13. Predicting the impact of antiretrovirals in resource poor settings: preventing HIV infections whilst controlling drug resistance. S Blower L Ma P Farmer S Koenig, Current Drug Targets - Infectious Disorders 2003 3 345 353 10.2174/1568005033480999
14. The impact of the ARV rollout on drug-resistant HIV in Africa: insights from empirical data & theoretical models. S Blower E Bodine J Kahn W McFarland, AIDS 2005 19 1 14 10.1097/00002030-200501030-00001 15627028
15. th 2007 17225857 10.1371/journal.pone.0000152
16. Designing equitable antiretroviral allocation strategies in resource-constrained countries. DP Wilson S Blower, PLoS Medicine 2006 3 e160 Epub 2006 March 28 16563042 10.1371/journal.pmed.0030160
17. Regional variations in the trends of transmitted HIV drug resistance in Canada. E Yan S Zhang GC Jayaraman NJ Goedhuis JI Brooks H Merks ML Rekart E Wong AE Singh M Dawood M Wood E Laing P Sandstrom CP Archibald, Public Health Agency of Canada Preprint 2007
18. Waiting times for the appearance of Cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection. Y Liu JI Mullins JE Mittler, Virology 2006 347 140 146 10.1016/j.virol.2005.11.036 16387340
19. Comment on "Evidence for positive epistasis in HIV-1". K Wang JE Mittler R Samudrala, Science 2006 312 5775 848 10.1126/science.1109904 16690844
20. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. RJ Smith LM Wahl, Bulletin of Mathematical Biology 2005 67 783 813 10.1016/j.bulm.2004.10.004 15893553
21. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects. RJ Smith LM Wahl, Bulletin of Mathematical Biology 2004 66 1259 1283 10.1016/j.bulm.2003.12. 004 15294425
22. Natural variation in HIV infection: Monte Carlo estimates that include CD8 effector cells. JM Heffernan LM Wahl, Journal of Theoretical Biology 2006 243 191 204 10.1016/j.jtbi.2006.05.032 16876200
23. Improving estimates of the basic reproductive ratio: Using both the mean and the dispersal of transition times. JM Heffernan LM Wahl, Theoretical Population Biology 2006 70 135 145 10.1016/j.tpb.2006.03.003 16712889
24. Monte Carlo estimates of natural variation in HIV infection. JM Heffernan LM Wahl, Journal of Theoretical Biology 2005 236 137 153 10.1016/j.jtbi.2005. 03.002 16005307
25. Emergence of drug-resistance: implications for antiviral control of pandemic influenza. ME Alexander CS Bowman Z Feng M Gardam SM Moghadas G Röst J Wu P Yan, Proc Biol Sci 2007 274 1619 1675 1684 doi:10.1098/rspb. 2007.0422 10.1098/rspb.2007.0422 17507331
26. The structure and function of complex networks. MEJ Newman, SIAM Rev 2003 45 167 256 10.1137/S003614450342480
27. The spread of epidemic disease on networks. ME Newman, Phys Rev E Stat Nonlin Soft Matter Phys 2002 66 1 Pt 2 art no.-016128
28. Collective dynamics of "small-world" networks. DJ Watts SH Strogatz, Nature 1998 393 440 442 10.1038/30918 9623998
29. Statistical mechanics of complex networks. R Albert AL Barabasi, Reviews of Modern Physics 2002 74
30. Evaluation of targeted influenza vaccination strategies via population modeling. J Glasser D Taneri W Thompson J Chuang J Wu P Tull J Alexander, preprint 2007